From Wikipedia, the free encyclopedia
|Chemical and physical data|
|Molar mass||78.7 kg/mol|
This drug was developed by Teva Pharmaceutical Industries, Inc. As of 2012, development of placulumab has been discontinued.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Placulumab, American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|